211 related articles for article (PubMed ID: 11871364)
1. Potential masking effect on dyspnoea perception by short- and long-acting beta2-agonists in asthma.
van Schayck CP; Bijl-Hofland ID; Cloosterman SG; Folgering HT; van der Elshout FJ; Van Weel C
Eur Respir J; 2002 Feb; 19(2):240-5. PubMed ID: 11871364
[TBL] [Abstract][Full Text] [Related]
2. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists.
van Schayck CP; Cloosterman SG; Bijl-Hofland ID; van den Hoogen H; Folgering HT; van Weel C
Respir Med; 2002 Mar; 96(3):155-62. PubMed ID: 11908511
[TBL] [Abstract][Full Text] [Related]
3. Inhaled corticosteroids, combined with long-acting beta(2)-agonists, improve the perception of bronchoconstriction in asthma.
Bijl-Hofland ID; Cloosterman SG; Folgering HT; van den Elshout FJ; van Weel C; van Schayck CP
Am J Respir Crit Care Med; 2001 Sep; 164(5):764-9. PubMed ID: 11549530
[TBL] [Abstract][Full Text] [Related]
4. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
5. Unaltered perception of dyspnoea during treatment with long-acting beta2-agonists.
van der Woude HJ; Aalbers R
Eur Respir J; 2001 Aug; 18(2):269-71. PubMed ID: 11529283
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients.
Cloosterman SG; Bijl-Hofland ID; van Herwaarden CL; Akkermans RP; van Den Elshout FJ; Folgering HT; van Schayck CP
Chest; 2001 May; 119(5):1306-15. PubMed ID: 11348933
[TBL] [Abstract][Full Text] [Related]
7. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
8. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
9. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.
Aziz I; Lipworth BJ
Chest; 1999 Mar; 115(3):623-8. PubMed ID: 10084466
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma.
Kozlik-Feldmann R; von Berg A; Berdel D; Reinhardt D
Eur J Med Res; 1996 Jul; 1(10):465-70. PubMed ID: 9438143
[TBL] [Abstract][Full Text] [Related]
11. Relief of dyspnoea by beta2-agonists after methacholine-induced bronchoconstriction.
van der Woude HJ; Postma DS; Politiek MJ; Winter TH; Aalbers R
Respir Med; 2004 Sep; 98(9):816-20. PubMed ID: 15338791
[TBL] [Abstract][Full Text] [Related]
12. Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma.
Becker AB; Simons FE
J Allergy Clin Immunol; 1989 Dec; 84(6 Pt 1):891-5. PubMed ID: 2574732
[TBL] [Abstract][Full Text] [Related]
13. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.
Wong AG; O'Shaughnessy AD; Walker CM; Sears MR
Eur Respir J; 1997 Feb; 10(2):330-6. PubMed ID: 9042628
[TBL] [Abstract][Full Text] [Related]
14. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol.
Lipworth BJ; Aziz I
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):88-92. PubMed ID: 9893190
[TBL] [Abstract][Full Text] [Related]
15. Airway responsiveness to beta-adrenergic agonist (salbutamol) in asthma.
Boskabady MH; Saadatinejad M
J Asthma; 2003 Dec; 40(8):917-25. PubMed ID: 14736092
[TBL] [Abstract][Full Text] [Related]
16. Airway responsiveness as a direct factor contributing to the dyspnoea perception in asthma.
Koh YI; Choi IS; Lim H
Respir Med; 2001 Jun; 95(6):464-70. PubMed ID: 11421503
[TBL] [Abstract][Full Text] [Related]
17. Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment.
Yates DH; Sussman HS; Shaw MJ; Barnes PJ; Chung KF
Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1170-4. PubMed ID: 7551366
[TBL] [Abstract][Full Text] [Related]
18. [Asthma patients' perception of dyspnea during acute bronchoconstriction].
Martínez-Moragón E; Perpiñá M; Belloch A; de Diego A; Martínez-Francés ME
Arch Bronconeumol; 2003 Feb; 39(2):67-73. PubMed ID: 12586046
[TBL] [Abstract][Full Text] [Related]
19. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol.
Aziz I; Tan KS; Hall IP; Devlin MM; Lipworth BJ
Eur Respir J; 1998 Sep; 12(3):580-4. PubMed ID: 9762783
[TBL] [Abstract][Full Text] [Related]
20. A comparison of breathlessness during spontaneous asthma and histamine-induced bronchoconstriction.
Boudreau D; Styhler A; Gray-Donald K; Martin JG
Clin Invest Med; 1995 Feb; 18(1):25-32. PubMed ID: 7768063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
